



BSI Standards Publication

***In vitro* diagnostic Next Generation Sequencing (NGS) workflows**

Part 2: Human RNA examination

National foreword

This Published Document is the UK implementation of CEN/TS 17981-2:2023.

The UK participation in its preparation was entrusted to Technical Committee CH/212, IVDs.

A list of organizations represented on this committee can be obtained on request to its committee manager.

Contractual and legal considerations

This publication has been prepared in good faith, however no representation, warranty, assurance or undertaking (express or implied) is or will be made, and no responsibility or liability is or will be accepted by BSI in relation to the adequacy, accuracy, completeness or reasonableness of this publication. All and any such responsibility and liability is expressly disclaimed to the full extent permitted by the law.

This publication is provided as is, and is to be used at the recipient's own risk.

The recipient is advised to consider seeking professional guidance with respect to its use of this publication.

This publication is not intended to constitute a contract. Users are responsible for its correct application.

This publication is not to be regarded as a British Standard.

© The British Standards Institution 2023
Published by BSI Standards Limited 2023

ISBN 978 0 55 21304 1

ICS 11.06.10

Compliance with a Published Document cannot confer immunity from legal obligations.

This Published Document was published under the authority of the Standards Policy and Strategy Committee on 31 December 2023.

Amendments/corrigenda issued since publication

Date	Text affected
------	---------------

ICS 11.100.10

English Version

In vitro diagnostic Next Generation Sequencing (NGS)
 workflows - Part 2: Human RNA examination

Diagnostic *in vitro* Séquençage de nouvelle génération
 (NGS) - Partie 2 : Examens de l'ARN humain

Next Generation Sequencing (NGS) Arbeitsabläufe für
 die *In-vitro*-Diagnostik - Teil 2: Untersuchung von
 menschlicher RNA

This Technical Specification (CEN/TS) was approved by CEN on 15 October 2023 for provisional application.

The period of validity of this CEN/TS is limited initially to three years. After two years the members of CEN will be requested to submit their comments, particularly on the question whether the CEN/TS can be converted into a European Standard.

CEN members are required to announce the existence of this CEN/TS in the same way as for an EN and to make the CEN/TS available promptly at national level in an appropriate form. It is permissible to keep conflicting national standards in force (in parallel to the CEN/TS) until the final decision about the possible conversion of the CEN/TS into an EN is reached.

CEN members are the national standards bodies of Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Republic of North Macedonia, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Türkiye and United Kingdom.



EUROPEAN COMMITTEE FOR STANDARDIZATION
 COMITÉ EUROPÉEN DE NORMALISATION
 EUROPÄISCHES KOMITEE FÜR NORMUNG

CEN-CENELEC Management Centre: Rue de la Science 23, B-1040 Brussels

Contents		Page
European foreword		4
Introduction		5
1	Scope.....	6
2	Normative references.....	7
3	Terms and definitions.....	7
4	General requirements.....	20
4.1	General.....	20
4.2	Examination design.....	21
4.3	Examination development	25
4.4	Examination performance verification and validation.....	25
4.5	Technical examination performance characteristics.....	30
5	Pre-examination processes for examination development	31
5.1	General.....	31
5.2	Human RNA isolation	33
5.2.1	General.....	33
5.2.2	Isolation from formalin fixed and paraffin embedded (FFPE) tissue	33
5.2.3	Isolation from fresh frozen tissue.....	33
5.2.4	Isolation from fine needle aspirates (FNA)	33
5.2.5	Isolation from whole blood	33
5.2.6	Isolation of circulating cell free RNA from plasma.....	34
5.3	RNA sample quality and quantity evaluation	34
6	Examination processes for examination development.....	36
6.1	Sequencing library preparation for examination development.....	36
6.1.1	General.....	36
6.1.2	Sequencing library preparation steps.....	36
6.1.3	RNA sequencing (RNA-Seq).....	40
6.2	Sequencing examination development.....	43
6.2.1	General.....	43
6.2.2	Techniques	43
6.2.3	Sequencing quality control.....	44
6.3	Data analysis requirements for examination development.....	44
6.4	Quality control (QC) requirements for examination development.....	45
6.4.1	General.....	45
6.4.2	RNA Sequencing.....	45
7	Requirements for the development of the examination reporting tool	46
7.1	General.....	46
7.2	Report attributes	47
7.3	Report content	47
8	Implementation of the <i>in vitro</i> diagnostic NGS workflow into routine practice	48
9	Reporting and interpretation of results	49
10	Quality assurance procedures	50
10.1	General.....	50

10.2	Performance monitoring, optimization of the examination and interlaboratory comparison	50
Annex A	(normative) <i>in vitro</i> diagnostic NGS workflow for single-cell analyses.....	51
A.1	General information and requirements on single-cell analyses	51
A.2	Pre-examination processes for examination development	52
A.2.1	General information of applicable procedures	52
A.2.2	Requirements for CTCs from blood specimen collection to CTC isolation	52
A.2.3	Requirements for fresh frozen/FFPE human tissue from specimen collection to isolation of single cells.....	52
A.2.4	Human RNA isolation	54
A.2.5	RNA sample quality evaluation.....	55
A.3	Examination phase for examination development	55
A.3.1	Sequencing library preparation for examination development for CTCs and single cells from tissues	55
A.3.2	Sequencing examination development for CTCs and single cells from tissues.....	55
A.3.3	Data analysis requirements for examination development for CTCs and single cells from tissues	56
A.3.4	QC requirements for examination development	57
A.4	Implementation of the <i>in vitro</i> diagnostic NGS workflow into routine practice.....	57
A.5	Reporting and interpretation of results.....	57
A.6	Quality assurance procedures	57
Annex B	(normative) Exemplary <i>in vitro</i> diagnostic NGS workflow for spatial transcriptomics	58
Annex C	(informative) <i>in vitro</i> diagnostic NGS workflow scheme for the examination of RNA	59
Bibliography	60

European foreword

This document (CEN/TS 17981-2:2023) has been prepared by Technical Committee CEN/TC 140 “*In vitro* diagnostic medical devices”, the secretariat of which is held by DIN.

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. CEN shall not be held responsible for identifying any or all such patent rights.

A list of all parts in this series can be found on the CEN website: www.cencenelec.eu.

Any feedback and questions on this document should be directed to the users' national standards body. A complete listing of these bodies can be found on the CEN website.

According to the CEN/CENELEC Internal Regulations, the national standards organizations of the following countries are bound to announce this Technical Specification: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Republic of North Macedonia, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Türkiye and the United Kingdom.

Introduction

Molecular *in vitro* diagnostics has enabled significant progress in medicine. Further progress is expected by new technologies analysing profiles of nucleic acids, proteins, and metabolites in human tissues and body fluids. Next Generation Sequencing (NGS) takes a prominent place in the series of molecular techniques used for diagnostics. It facilitates sequence analysis of nucleic acids that can result in precise information for diagnosis and progression of diseases.

The NGS technique, however, has a very complex workflow that contains many steps. The target nucleic acids can originate from different sources, e.g. tissues, blood, and body fluids. The profiles of the isolated RNA can change during specimen collection, transport, storage and processing (e.g. formalin fixation) making the outcome from diagnostics or research unreliable or even impossible because the subsequent analytical assay will not determine the situation in the patient but an artificial profile generated during the pre-examination process. The available material can be small, the cells in a tissue can be dispersed heterogeneously (e.g. ratio of tumour to normal), the target nucleic acids can be circulating in blood or body fluids free of cells or in circulating cells (e.g. circulating tumour cells (CTCs)). For a successful and reliable sequence result, a suitable strategy needs to be chosen for every case depending on the available material and disease conditions. Therefore, the NGS workflow can differ from case to case, and the NGS workflow steps need to be carefully considered and chosen to get a sound and reliable result to determine the best available treatment for the patient. In addition, sequence platforms can differ in their technique (e.g. detection of a change in a current or fluorescence) and approach (e.g. whole transcriptome, panels, short-read sequencing, long-read sequencing) for sequence assessment. The bioinformatics analysis can differ in approach and ability to detect non-conformities and unreliable sequence results. To enable such capabilities, NGS metadata needs to be collected during all workflow steps from the patient to the reporting. In addition, controls and added controls need to be analysed properly. This way non-conformities or detected unreliabilities can be reported to the patient and the treating physician. The reporting of diagnostic NGS results can differ in clarity and depth, which can lead to different interpretations.

Standardization of the entire NGS workflow from specimen collection to the reporting of the results to the patient and the treating physician is needed for the development of reliable NGS examinations.

This document draws upon previous work to standardize the steps for NGS examinations from tissues, blood and body fluids in what is referred to as the pre-examination phase (sample collection), the examination phase (library preparation, sequencing), and the post-examination phase (analysis and reporting).

In this document, the following verbal forms are used:

- “shall” indicates a requirement;
- “should” indicates a recommendation;
- “may” indicates a permission;
- “can” indicates a possibility or a capability.

1 Scope

This document specifies requirements and gives recommendations for next generation sequencing (NGS) workflows for *in vitro* diagnostics and biomedical research. This document covers the pre-examination processes, human RNA isolation, sequencing library preparation, sequencing, sequence analysis and reporting of the examination of sequences for diagnostic purposes from isolated RNA from, e.g. formalin-fixed and paraffin embedded tissues, fresh frozen tissues, fine needle aspirates (FNA), whole blood, circulating tumour cells (CTCs), exosomes and other extracellular vesicles, and circulating cell free RNA from plasma.

NOTE 1 Typical applications include, but are not limited to, NGS for oncology and clinical genetics, certain single cell analyses.

This document is applicable to molecular *in vitro* diagnostic examinations including laboratory developed tests performed by medical laboratories, molecular pathology laboratories and molecular genetic laboratories. This document is also applicable to laboratory customers, *in vitro* diagnostics developers and manufacturers, biobanks, institutions, and organisations performing biomedical research.

This document is not applicable for in situ sequencing, forensic sequencing, sequencing of pathogens or microorganisms and microbiome analysis.

NOTE 2 International, national or regional regulations or requirements or multiple of them can also apply to specific topics covered in this document.

2 Normative references

The following documents are referred to in the text in such a way that some or all of their content constitutes requirements of this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

CEN/TS 17390-1, *Molecular in vitro diagnostic examinations — Specifications for pre-examination processes for circulating tumor cells (CTCs) in venous whole blood — Part 1: Isolated RNA*

CEN/TS 17688-1:2021, *Molecular in vitro diagnostic examinations - Specifications for pre-examination processes for Fine Needle Aspirates (FNA) — Part 1: Isolated cellular RNA*

CEN/TS 17747, *Molecular in vitro diagnostic examinations — Specifications for pre-examination processes for exosomes and other extracellular vesicles in venous whole blood — DNA, RNA and proteins*

CEN/TS 17742, *Molecular in vitro diagnostic examinations — Specifications for pre-examination processes for venous whole blood — Isolated circulating cell free RNA from plasma*

EN ISO 15189:2022, *Medical laboratories — Requirements for quality and competence (ISO 15189:2022)*

EN ISO/IEC 17020:2012, *Conformity assessment — Requirements for the operation of various types of bodies performing inspection (ISO/IEC 17020:2012)*

EN ISO/IEC 17025:2017, *General requirements for the competence of testing and calibration laboratories (ISO/IEC 17025:2017)*

EN ISO 20166-1:2018, *Molecular in vitro diagnostic examinations — Specifications for pre-examination processes for formalin-fixed and paraffin-embedded (FFPE) tissue — Part 1: Isolated RNA (ISO 20166-1:2018)*

EN ISO 20184-1:2018, *Molecular in vitro diagnostic examinations — Specifications for pre-examination processes for frozen tissue — Part 1: Isolated RNA (ISO 20184-1:2018)*